The Edinburgh Protein Production Facility (EPPF) in Edinburgh, Scotland, UK, is one of Europe’s biggest and better-equipped protein research facilities. In affiliation with the University of Edinburgh, it was opened in 2008 to offer a range of custom-designed, managed facilities to assist with and facilitate various protein-related life science developments.
Since 2008, the EPPF has made contributions to the research of over 350 scientific publications across an extensive range of disciplines. The EPPF has accommodated over 650 registered users from 170 research groups from Edinburgh and beyond, that span Biology, Chemistry, and Physics, as well as Medicine.
Image Credit: PHC Europe B.V.
The Edinburgh Protein Production Facility is a ‘research hotel'. The researchers that use it book time and space on our equipment and have access to our staff expertise, if needed. We have developed the EPPF to provide all the facilities necessary for protein research in one place. We train students, postdoctoral researchers, Principle Investigators (PIs): from high-school work-placement students, right the way through to established researchers. As we train, we encourage them to do a lot of the work themselves.”
Dr. Martin Wear, Senior Lecturer in Biochemistry, University of Edinburgh’s School of Biological Sciences and Manager, EPPF
Roots in molecular biology
The initial concept and framework for the EPPF were based on work conducted by Dr. Wear and Professor Walkinshaw in creating analytical methodologies for producing, purifying, screening and analyzing protein ligand complexes and proteins.
This work underscored an extensive amount of investigation into the field of drug design, protein production and molecular recognition. The principal investors in the EPPF and subsequent research projects have been the University of Edinburgh and the Wellcome Trust.
“Right from the very beginning, we knew that the research hotel would need to have really experienced postdoctoral scientists that had been involved in their own research projects, and in driving both their own and other research themes forward, as staff,” explained Dr. Wear.
The core staff team currently consists of five experienced postdoctoral scientists possessing a wide variety of expertise, such as traditional biochemistry, structural biology, molecular biology, small molecule chemistry, protein production and biophysics.
“Our core scientists are not just good technicians; they are interested in the ‘nuts and bolts’ of the equipment and the experiments that people are using and performing, but at the same time, they have a really high-level understanding of theory and academic input. Therefore, they understand the limitations of the equipment in the Facility, and how to make the best use of it and the reagents,” says Dr. Wear.
“This means that the output from the downstream research, using the best quality reagents, the best quality proteins, is more effective and efficient with far better quality results. It’s also informative from the user’s point of view, because they’re working on the project with genuine experts and they pick up invaluable tips and insight.”
While the restrictions imposed by the Covid-19 pandemic present a number of problems, the EPPF’s greatest challenge is sustaining and upgrading its equipment to the latest specification.
“This is critical, but it is expensive. To maintain this world class output from the biomedical scientific community we need to constantly be at the edge of what the equipment and science can do, and make sure that the platforms are coming online to enable people to achieve that,” said Dr. Wear. “One of the unique things about the EPPF, is that we try to keep the costs for users as low as possible. However, strategic support from the funding bodies, institutions, and the University is then vital to keep the Facility running. Overall though, the outputs and the value from it are far greater than the sum of the parts.”
The University of Edinburgh and the Wellcome Trust have continued with their support which has allowed the EPPF to substantially invest in equipment that is diverse enough to support an extensive range of research requirements.
“The research hotel model was designed to create access to as varied a platform and user as possible,” said Dr. Wear.
The EPPF has installed advanced liquid chromatography systems that have been set up in various configurations to offer as much flexibility for production and purification as possible; capacity for the culture of mammalian cells, bacteria and yeast; and an exhaustive collection of analytical instruments for analyzing the biophysical state of protein complexes and proteins.
The institute also has surface plasmon resonance (SPR) instruments for kinetic investigations, calorimetry instruments for the study of thermodynamics and a range of spectroscopy and light scattering technologies, which can be employed to determine and define the size, shape, and activity of proteins or protein reagents in their native solution states.
It’s really important to have all the equipment in one place, because it allows people to either ‘cherry-pick‘ a particular platform for their workflow, or essentially, use us as a proxy for their own lab, for the whole pipeline of work.”
Dr. Martin Wear
Image Credit: PHC Europe B.V.
Furthermore, the success of the research environment itself is also vitally important.
“The core equipment won’t function, unless there is a good supporting infrastructure around it,” said Dr. Wear. “Our essentials are centrifuges, incubators, and -80 °C freezers, core consumables and reagents, as well as the building itself. If you don’t have these in place, it doesn’t really matter how much high-end equipment you’ve got, you can’t use it effectively.”
“Our new PHCbi equipment was acquired with a set of resources and funds that exist to support efforts to innovatively increase the sustainability of the University’s infrastructure, the core equipment, and the way that it runs, with a view to really seriously reducing the energy costs and carbon footprint of the whole University. The University of Edinburgh has set a target to be carbon neutral by 2040. We calculated that the energy saving on the new PHCbi cabinets versus old ones, was approximately £6,000 a year on electricity alone, and about 11 tonnes of CO2 equivalent.” he explained. “In addition, people have commented that the new PHCbi cabinets are really quiet and run very smoothly. It’s actually nice to be in the labs now, whereas before, it was really quite noisy. They make the work environment more conducive, which is really good for everyone,” he added.
“We calculated that the energy saving on the new PHCbi cabinets versus old ones, was approximately £6,000 a year on electricity alone, and about 11 tonnes of CO2 equivalent.”
While Dr. Wear is of the opinion that there are many alternative suppliers on the market selling equipment with reasonable comparable prices and specs, he believes PHCbi equipment offers a number of distinct advantages.
“Taking into account the build quality, the cost per unit efficiency, and any bespoke alterations that you might want, the PHCbi units have always featured in the top 20%. It is their reliability however, that makes them stand out. For price, performance and reliability, PHCbi rank in the top 10% of instrumentation when it comes to considering what to buy,” he said. “PHC Europe have achieved a balance that includes providing real service to the customer, whether it’s on technical advice, pricing or reliability. And because we’ve had a long-term relationship with them, and my PHC rep, Cheryl Swinton-Aitken, has always been really amenable, it just makes that relationship much more productive, both for them and for us.”
Trends in protein research
The EPPF has a well-established tradition of working with immunophilin proteins. These small proteins are part of a big family that is at the heart of the activation of T-cells and the immune response.
In relation to this, it is known for its study of the molecular details of the interaction between the cyclophilins and the drug cyclosporine, provided to organ transplant patients to thwart organ rejection, and is mediated directly by this family of proteins. They are also somehow involved in the infectious cycle of viruses like hepatitis and HIV.
PR-1412-PE: While the EPPF has utilized PHCbi equipment for a significant number of years, it has recently acquired 6 x PHCbi MPR-1412 Medical/ Pharmaceutical Refrigerators to offer refrigeration ranging from 2 °C to 23 °C. The units have been intentionally acquired to support work with the ÄKTATM protein purification equipment.
“There is a lot of interest in developing novel inhibitors for these proteins to develop new therapeutics and treatments. As we have a long history of working on them, we have also developed a worldwide reputation as being the best source for getting hold of those proteins as reagents for research, and also for their detailed biophysical characterization,” explained Dr. Wear. “Big biopharma has preferentially come to us for these proteins and for the work.”
One global trend in protein science is the miniaturization of protein production and characterization workflows in cryo-electron microscopy analysis. Major advances in the technological region over the last few years make it possible to acquire atomic resolution structures utilizing the technique.
A smaller amount of material is required for the comparison of the two conventional atomic resolution techniques: X-Ray crystallography and NMR.
“There’s been a general shift in the scale for production to meet that demand, which means that the equipment, as well as the up- and downstream processing, has become more sensitive and higher throughput, because less sample is needed to process. In the next five years, I can see that technique becoming routine,” he continued.
The Covid-19 pandemic has had a significant impact on protein research in several ways.
We were involved in rapid response Covid-19 research and part of a Covid-19 protein production consortium, which comprised of a network of 10 laboratories across the country set up by the Wellcome Trust UK and the Rosalind Franklin Institute. The consortium was designed to try and provide a set of laboratories and resources to produce reagents for Covid-19 research, especially for those people who were busy with research, but didn’t necessarily have the facilities to make the viral proteins or the expertise. The consortium was there to provide quality regents to facilitate novel ideas to try and address certain questions about the virus’ replication, or the pandemic, or distribution of new therapeutics etc,”
Dr. Wear Martin
However, another consequence of the pandemic has been that of limited access to the facilities.
“We were allowed to stay open, but with restrictions on, for example, how many people could be in the lab, in each room, etc. This has delayed some of our training and teaching activities, but we have taken on much more service work than we would normally do and have worked 24/7 in shifts right the way through the pandemic to try and push projects through,” he added.
For researchers, the protein complexes and the proteins that they need and want to study have become far more complex than ever before.
“Proteins that we are now trying to research tend to be multi-component and are large and complicated, and can’t be made simply anymore,” remarked Dr. Wear. “It’s become more expensive to make them. More complex production platforms, mammalian cells or insect cells are needed. It is just getting harder and harder to make the materials required to carry out research with. Without lots of experience in doing that, a lot of these projects would never get off the ground without having access to a core facility like the EPPF.”
For additional information visit: www.ed.ac.uk/biology/research/facilities/edinburgh-protein-production-facility-eppf
- 2021. Fast acting allosteric inhibitors of phosphofructokinase block trypanosome glycolysis and can cure acute African trypanosomiasis in mice. Nat Commun. Feb 16;12(1):1052.doi: 10.1038/s41467-021-21273-6. Iain W. McNae, James Kinkead, Divya Malik, Li-Hsuan Yen, Martin K. Walker, Chris Swain, Scott P. Webster, Nick Gray, Peter M. Fernandes, Elmarie Myburgh, Elizabeth A. Blackburn, Ryan Ritchie, Carol Austin, Martin A. Wear, Adrian J. Highton, Andrew J. Keats, Antonio, Jacqueline Dornan, Jeremy C. Mottram, Paul A.M. Michels, Simon Pettit, Malcolm D. Walkinshaw.
- 2020. A helminth-derived suppressor of ST2. Elife. May 18;9:e54017. doi: 10.7554/eLife.54017. Vacca F, Chauché C, Jamwal A, Hinchy EC, Heieis G, Webster H, Ogunkanbi A, Sekne Z, Gregory WF, Wear M, PeronaWright G, Higgins MK, Nys JA, Cohen ES, McSorley HJ.
- 2017. Molecular Basis for Cell Cycle Control of Mis18 Complex Assembly, an Essential Regulator of Centromere Inheritance. EMBO Rep. 2017 Apr 4. pii: e201643564. doi: 10.15252/embr.201643564. Frances Spiller, Bethan Medina-Pritchard, Maria Alba Abad, Martin A. Wear, Oscar Molina, William C. Earnshaw and A. Arockia Jeyaprakash.
- 2017. Thermo-kinetic analysis space expansion for cyclophilin-ligand interactions; identification of a new non-peptide inhibitor using Biacore™ T200. FEBS Open Bio. 23;7(4):533-549. M.A. Wear, M. Nowicki, I. McNae and MD. Walkinshaw.
- 2016 Biophysical characterization and activity of lymphostatin, a multifunctional virulence factor of attaching & effacing Escherichia coli. J. Biol. Chem. 11;291(11):5803-16. Robin L. Cassady-Cain, Elizabeth A. Blackburn, Husam Alsarraf, Emil Dedic, Andrew G. Bease, Bettina Bouttcher, Ren Joslashrgensen, Martin Wear, and Mark P. Stevens.
- 2015 A Streamlined, Automated Protocol for the Production of Milligram Quantities of Untagged Recombinant Rat Lactate Dehydrogenase A Using ÄKTAxpressTM. PLoS One.
- 2015 Dec 30;10(12):e0146164. doi: 10.1371/journal.pone.0146164. eCollection. Nowicki MW, Blackburn EA, McNae IW, Wear MA.
- 2007. Experimental determination of van der waals energies in a biological system. Angew Chem Int Ed Engl. 2007;46(34):6453-6. doi: 10.1002/anie.200702084. Wear MA, Kan D, Rabu A, Walkinshaw MD.
Founded in 1990 as subsidiary of the PHC Holdings Corporation, it is our mission to become a leading, trusted brand for sustainable healthcare and biomedical product solutions, which support the work of our customers to improve the health and well-being of people around the world.
For more than 25 years now, we respond to the needs of our pharmaceutical, biotechnology, hospital/clinical and industrial customers, offering an unique perspective on scientific research in general. As a result we play a critical role in product development for worldwide applications and have established a reputation as a manufacturer of high-quality and innovative medical and laboratory equipment.
Long lasting relationships have been built with leading pharmaceutical, healthcare and biotechnology companies as well as with major academic and research institutes in Europe. PHC Europe B.V. has set the standard in many aspects. V.I.P. panels, Cool Safe compressors, Active Background Contamination Control and the world’s first -152°C ULT freezer. Where PHC Europe B.V. took the initiative, the others followed. This made us a very important player in both the ultra-low temperature and the CO2 market.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.